Effect of Letrozol in cell proliferation marker of breast cancer patients
Phase 3
- Conditions
- Breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT20101104005101N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Breast caner patients
Early stage of disease
With hormone receptor positive
Postmenopausal women
Exclusion Criteria
Metastatic breast cancer
Premenopausal women
Other sub-types of breast cancer
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cell proliferation factor (Ki67). Timepoint: Measurement of ki67% level at the beginning of the study (before intervention) and one week after using Letrozol tablet. Method of measurement: Ki-67 will be calculated using scoring systems to estimate a proliferation index (PI); the number of positively stained tumor nuclei divided by the total number of nuclei in a specific region by pathologists.
- Secondary Outcome Measures
Name Time Method